Chromocell Therapeutics (CHRO) Competitors $0.64 -0.01 (-1.45%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends CHRO vs. NRXP, CARA, ACXP, AIM, TXMD, HCWB, MRNS, PMCB, AWH, and SLGLShould you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include NRx Pharmaceuticals (NRXP), Cara Therapeutics (CARA), Acurx Pharmaceuticals (ACXP), AIM ImmunoTech (AIM), TherapeuticsMD (TXMD), HCW Biologics (HCWB), Marinus Pharmaceuticals (MRNS), PharmaCyte Biotech (PMCB), Aspira Women's Health (AWH), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry. Chromocell Therapeutics vs. NRx Pharmaceuticals Cara Therapeutics Acurx Pharmaceuticals AIM ImmunoTech TherapeuticsMD HCW Biologics Marinus Pharmaceuticals PharmaCyte Biotech Aspira Women's Health Sol-Gel Technologies NRx Pharmaceuticals (NASDAQ:NRXP) and Chromocell Therapeutics (NYSE:CHRO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Does the MarketBeat Community prefer NRXP or CHRO? NRx Pharmaceuticals received 12 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformNRx PharmaceuticalsOutperform Votes13100.00% Underperform VotesNo VotesChromocell TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Does the media prefer NRXP or CHRO? In the previous week, NRx Pharmaceuticals and NRx Pharmaceuticals both had 2 articles in the media. NRx Pharmaceuticals' average media sentiment score of 1.46 beat Chromocell Therapeutics' score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chromocell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer NRXP or CHRO? NRx Pharmaceuticals currently has a consensus target price of $32.00, suggesting a potential upside of 2,033.33%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Chromocell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of NRXP or CHRO? 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.0% of Chromocell Therapeutics shares are owned by institutional investors. 19.0% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 16.4% of Chromocell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is NRXP or CHRO more profitable? Company Net Margins Return on Equity Return on Assets NRx PharmaceuticalsN/A N/A -449.16% Chromocell Therapeutics N/A N/A -453.90% Which has preferable valuation and earnings, NRXP or CHRO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNRx PharmaceuticalsN/AN/A-$30.15M-$2.14-0.70Chromocell TherapeuticsN/AN/A-$7.38MN/AN/A SummaryNRx Pharmaceuticals beats Chromocell Therapeutics on 8 of the 10 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRO vs. The Competition Export to ExcelMetricChromocell Therapeutics IndustryMedical SectorNYSE ExchangeMarket Cap$3.88M$2.13B$5.14B$19.19BDividend YieldN/A14.40%5.09%3.62%P/E RatioN/A10.7490.1341.30Price / SalesN/A151.331,117.0917.51Price / CashN/A14.4143.1021.28Price / Book-0.392.014.785.32Net Income-$7.38M$59.91M$120.31M$989.88M7 Day Performance9.98%-1.97%-1.92%-3.54%1 Month Performance-2.50%-1.62%13.65%-4.73%1 Year PerformanceN/A8.75%28.34%11.57% Chromocell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHROChromocell TherapeuticsN/A$0.64-1.5%N/AN/A$3.88MN/A0.004Gap UpHigh Trading VolumeNRXPNRx Pharmaceuticals3.3017 of 5 stars$1.17-2.2%$32.00+2,627.4%-96.5%$14.19MN/A-0.562News CoveragePositive NewsCARACara Therapeutics4.2299 of 5 stars$0.25-3.5%$2.32+817.7%-29.0%$13.87M$8.69M-0.1555News CoverageGap DownACXPAcurx Pharmaceuticals1.3843 of 5 stars$0.82-4.1%$12.00+1,363.4%-77.0%$13.85MN/A-0.783Gap UpAIMAIM ImmunoTech2.3673 of 5 stars$0.22-1.3%$2.75+1,172.0%-60.4%$13.79M$190,000.00-0.4720TXMDTherapeuticsMD0.4365 of 5 stars$1.19-2.9%N/A-53.8%$13.66M$1.30M0.00420Analyst ForecastGap UpHCWBHCW Biologics0.4069 of 5 stars$0.36+0.1%N/A-60.4%$13.51M$3.50M-0.3640Gap DownMRNSMarinus Pharmaceuticals4.3127 of 5 stars$0.23-11.2%$4.79+1,950.4%-97.6%$12.88M$31.47M-0.10110Analyst ForecastNews CoveragePMCBPharmaCyte Biotech0.4217 of 5 stars$1.67-2.9%N/A-24.8%$12.83MN/A2.612Earnings ReportAWHAspira Women's Health1.218 of 5 stars$0.76+0.7%$4.40+482.8%-69.7%$12.59M$9.15M-0.62110Analyst ForecastSLGLSol-Gel Technologies2.4245 of 5 stars$0.45-6.1%$5.00+1,010.6%-66.5%$12.54M$1.55M-1.3650 Related Companies and Tools Related Companies NRx Pharmaceuticals Competitors Cara Therapeutics Competitors Acurx Pharmaceuticals Competitors AIM ImmunoTech Competitors TherapeuticsMD Competitors HCW Biologics Competitors Marinus Pharmaceuticals Competitors PharmaCyte Biotech Competitors Aspira Women's Health Competitors Sol-Gel Technologies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CHRO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
